How Clinical Trials Accelerate Access to New and Effective Cancer Treatments

Jump To Section

• Clinical Trials for Cancer Patients
• Historical Cancer Drug Approval Process
• The Revolution of Targeted Therapies
• Modern FDA Approval Process
• Benefits of Early Clinical Trial Access
• The Critical Role of Genetic Testing
• The Future of Cancer Research
• Full Transcript

Clinical Trials for Cancer Patients

Clinical trials are a fundamental mechanism for bringing new and effective cancer treatments to patients, offering a potential pathway to therapy that may be more effective than standard options. Dr. Bruce Chabner, MD, a preeminent oncologist with decades of experience, emphasizes that while patients must be aware of the latest trials, they should also have a clear understanding of their specific goals and limitations. The central question, as posed by interviewer Dr. Anton Titov, MD, is how these trials ultimately help patients obtain better cancer therapy faster.

Historical Cancer Drug Approval Process

Dr. Bruce Chabner, MD, began his career in oncology research in 1967, a time when the drug development landscape was vastly different. The primary criterion for approving a new cancer medication was a demonstrable increase in overall patient survival. This gold standard meant that clinical trials were extensive and lengthy, often taking between 7 to 10 years to complete before a drug could be deemed effective and made widely available to the public.

This protracted and costly process offered little encouragement for pharmaceutical investment in oncology. Dr. Bruce Chabner, MD, notes that despite the challenges, a few cornerstone chemotherapies like Taxol, Cisplatin, and Doxorubicin emerged from this era. These drugs, which are still used today, required immense patience and resources to develop and prove their efficacy to regulators like the FDA.

The Revolution of Targeted Therapies

A major paradigm shift occurred approximately 15 years ago with the advent of targeted cancer medications. This breakthrough fundamentally changed the clinical trial process. Instead of testing a drug on a broad, unselected population and waiting a decade for survival data, researchers could now design trials for specific patient populations whose tumors had a known genetic target.

Dr. Bruce Chabner, MD, explains that this precision approach drastically shortened the medication development period from 10 years to just 2 or 3 years. In these modern trials, a new drug can be shown to be "outstandingly effective" by demonstrating high rates of tumor response (shrinkage) and significantly longer survival compared to standard treatment in that carefully selected group.

Modern FDA Approval Process

The ability to prove efficacy in early-phase clinical trials has revolutionized the regulatory approval process. Dr. Bruce Chabner, MD, highlights that the U.S. Food and Drug Administration (FDA) and its European counterparts now approve new cancer therapies based on compelling data from these initial studies, rather than mandating lengthy comparative Phase III trials in every instance.

This accelerated approval pathway means that breakthrough medications can be brought to market much faster than was possible in the past. This rapid translation of research from the lab to the clinic is a direct benefit of the targeted therapy model and provides a powerful tool for oncologists seeking the best options for their patients.

Benefits of Early Clinical Trial Access

For individual patients, the most significant advantage is the potential for early access to a highly effective therapy. Dr. Bruce Chabner, MD, confirms Dr. Titov's point that patients can be treated during a clinical trial, potentially gaining a substantial therapeutic benefit long before the drug is commercially available. This opportunity is especially critical for patients who have exhausted standard treatment options.

The key, according to Dr. Chabner, is getting into the "correct" clinical trial. The benefit is not guaranteed by trial participation alone; it is contingent on a patient's specific cancer biology aligning perfectly with the mechanism of the experimental treatment being studied.

The Critical Role of Genetic Testing

Identifying the correct trial is impossible without comprehensive genetic testing of the tumor. Dr. Bruce Chabner, MD, stresses that molecular profiling is the essential first step for any patient considering an experimental therapy. By understanding the unique genetic drivers and mutations of a tumor, oncologists can match patients to clinical trials investigating drugs designed to target those specific alterations.

This strategy of biomarker-driven enrollment ensures that patients most likely to respond are selected for the trial, which increases the chances of a positive outcome for the participant and generates clearer, more compelling data for the drug developers and regulators.

The Future of Cancer Research

The evolution described by Dr. Chabner points toward an increasingly personalized future for cancer medicine. The continued development of targeted therapies and immunotherapies will rely even more heavily on sophisticated clinical trials that use genetic biomarkers for patient selection. This approach maximizes efficiency in drug development and continues to accelerate the pace at which new, life-extending treatments reach the patients who need them most.

As Dr. Anton Titov, MD, discusses with experts like Dr. Chabner, patient education and awareness remain paramount. Understanding that clinical trials are a viable and often advantageous treatment option is the first step for many patients and families navigating a complex cancer diagnosis.

Full Transcript

Dr. Anton Titov, MD: How do clinical trials help cancer patients get better cancer treatments? How do clinical trials of cancer medicines help to get effective cancer therapy faster?

Dr. Bruce Chabner, MD: I've been in the oncology field a long time. I've been in cancer research efforts since 1967. I hate to admit it—it's that far back! Things were very different then.

The primary criterion for approving a cancer medication was the survival of cancer patients. This was the criteria for making a new cancer medication available to patients nationally. The cancer medication had to increase life expectancy, so that was the gold standard in those days.

There were some cancer medications approved with lesser standards, but usually it took a period of 7 to 10 years to complete the clinical trial of a cancer medication. Then you could say, "Yes, this is an effective cancer medication. We can now give it to a patient. We can sell it."

The pharmaceutical industry was not very encouraged to participate in cancer medication development. There were not many ideas, and we didn't understand cancer all that well.

Fortunately, a few really effective cancer medications came along, like Taxol, Cisplatin, and Doxorubicin. These are key cancer medications to treat cancer, and we still use them.

Each of these cancer medications took a long time in clinical development. It was really painful. Eventually, we got the kind of information that would convince the Food and Drug Administration to approve the cancer medication.

A major change took place about 15 years ago with the development of targeted cancer medications. It now became possible to find better cancer medications, which immediately provided a benefit in cancer clinical trials.

Before, we had a 10-year period of medication development. Now the medication development period was much shorter—it could be 2 to 3 years.

We had to go through long, complicated cancer medication development plans. We had to do comparisons of Group A versus Group B, where one group of cancer patients was treated with the cancer medication and the other group was not.

Now we can just do an initial clinical trial in a very carefully selected cancer patient population. We can show that the cancer medication is outstandingly effective—it produces cancer responses, induces tumor shrinking, and the majority of cancer patients are living longer than they would with standard treatment.

So there has really been a revolution in the cancer medication approval process. The Food and Drug Administration here in the US approves cancer medications rapidly. In Europe, the similar body that governs availability of cancer medications does the same.

Approval of new cancer therapy is based on these early clinical trials. We can bring a cancer medication to market much faster now than we could in the past, so that certainly helps cancer patients to be selected better.

Dr. Anton Titov, MD: Patients can potentially be treated during the clinical trial.

Dr. Bruce Chabner, MD: That's correct! You raise an important point. It's important for patients with cancer to be aware of the fact that experimental cancer medication trials can be very effective if you get into the correct clinical trial.

If you have the "correct" tumor—you have to do genetic testing of your tumor—and you find the correct cancer treatment clinical trial, then you can get much benefit out of new cancer treatment at a very early point.